Home › NDC Lookup › RxCUI directory › RxCUI 1374770

12 HR carbinoxamine maleate 0.8 MG/ML Extended Release Suspension — RxCUI 1374770

RxNorm drug concept · Semantic clinical drug
RxCUI 1374770 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1374770
Official name12 HR carbinoxamine maleate 0.8 MG/ML Extended Release Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascarbinoxamine maleate 4 MG per 5 ML 12 HR Extended Release Oral Suspension; carbinoxamine maleate 4 MG in 5 mL 12HR Extended Release Oral Suspension
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)17,259 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Carbinoxamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Carbinoxamine is an antihistamine that relieves allergy symptoms — things like a runny nose, sneezing, itchy or watery eyes, and skin reactions like hives or swelling. It also work...
  • What exactly does carbinoxamine help with?
  • Yes — drowsiness is one of the most common side effects, and it can be significant. Carbinoxamine is an older-style antihistamine that crosses into the brain, so it tends to be mor...
  • If you've been prescribed Karbinal ER or Carbinoxamine Maleate Extended-Release Oral Suspension, always shake the bottle well before measuring each dose. Use the measuring device p...
📖 Read our full Carbinoxamine guide →

🕸️ Concept Web — How 12 HR carbinoxamine maleate 0.8 MG/ML Extended R... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR carbinoxamine maleate 0.8 MG/ML Extended Release Suspension RxCUI 1374770

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Carbinoxamine 20220
    • Carbinoxamine maleate 91066
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Karbinal 1374771
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Carbinoxamine Extended Release Suspension 582331
    • Carbinoxamine maleate Extended Release Suspension 2648740
    • Carbinoxamine Oral Liquid Product 1160574
    • Carbinoxamine Oral Product 1160575
    • Carbinoxamine maleate Oral Liquid Product 2662317
    • Carbinoxamine maleate Oral Product 2659504
    • Carbinoxamine Extended Release Suspension [Karbinal] 1374773
    • Carbinoxamine maleate Extended Release Suspension [Karbinal] 2658886
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Carbinoxamine maleate 0.8 MG/ML SCDC · 1010695
  • Carbinoxamine Extended Release Suspension SCDF · 582331
  • Carbinoxamine maleate Extended Release Suspension SCDFP · 2648740
  • Carbinoxamine Oral Liquid Product SCDG · 1160574
  • Carbinoxamine Oral Product SCDG · 1160575
  • Carbinoxamine maleate Oral Liquid Product SCDGP · 2662317
  • Carbinoxamine maleate Oral Product SCDGP · 2659504

Brand-Name Concepts

  • 12 HR carbinoxamine maleate 0.8 MG/ML Extended Release Suspension [Karbinal] SBD · 1374776
  • Carbinoxamine maleate 0.8 MG/ML [Karbinal] SBDC · 1374772
  • Carbinoxamine Extended Release Suspension [Karbinal] SBDF · 1374773
  • Carbinoxamine maleate Extended Release Suspension [Karbinal] SBDFP · 2658886
  • Karbinal Oral Liquid Product SBDG · 1374774
  • Karbinal Oral Product SBDG · 1374775
  • Karbinal BN · 1374771

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 1374770 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
23594-0101-01 2 BOTTLE, PLASTIC in 1 CARTON (23594-101-01) / 30 mL in 1 B... Karbinal ER Aytu Therapeutics, LLC 2014-01-03
23594-0101-05 480 mL in 1 BOTTLE, PLASTIC (23594-101-05) Karbinal ER Aytu Therapeutics, LLC 2014-01-03
62542-0101-05 480 mL in 1 BOTTLE, PLASTIC (62542-101-05) Carbinoxamine Maleate Extended-Release Oral Suspension Neos Therapeutics, LP 2024-06-01
Observed labelers: Aytu Therapeutics, LLC (2) · Neos Therapeutics, LP (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$1.1217
Range $1.0475–$1.1958 · middle 50% $1.0846–$1.1587 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.